Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

SAN DIEGO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2008. For the third quarter of 2008, the Company reported a net loss of $17.7 million, or $(0.46) per share compared with a net loss of $27.2 million, or $(0.72) per share, for the same period in 2007. For the nine months, the Company reported a net loss of $59.8 million, or $(1.56) per share, as compared to $79.3 million, or $(2.09) per share, for the same period last year.

Revenues for the third quarter of 2008 were $0.8 million compared with $0.5 million for the same period last year. Revenues for the nine months ended September 30, 2008 were $3.2 million, compared with $0.7 million for the same period in 2007. The increase in revenues is primarily due to revenues recognized in 2008 under collaboration agreements with GlaxoSmithKline (GSK) and Dainippon Sumitomo Pharma Co., Ltd.

Research and development expenses decreased to $13.0 million during the third quarter of 2008 compared with $19.8 million for the same period in 2007. For the nine months ended September 30, 2008, research and development expenses were $43.4 million, compared to $57.6 million for the same period last year. The decrease in research and development expenses is primarily due to cost savings related to our restructuring in the fourth quarter of 2007.

General and administrative expenses were $3.5 million for the third quarter of 2008 and $9.6 million during the same period last year. For the nine months ended September 30, 2008, general and administrative expenses were $16.4 million, compared to $26.7 million for the first nine months of 2007. The reduction in general and admin
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 With the ability to record ... for more than 15 minutes, Fastec Imaging has brought the ... high speed imaging. “Finally, a high speed camera that can ... in our everyday lives.” proclaims Matt Kearney, VP of Sales ... been to demystify and simplify the traditionally complicated workflow of ...
(Date:7/23/2014)... 23, 2014 a2z Inc. announces that ... App, AACC Pathfinder, in its 2014 Annual Meeting ... meeting is planned for July 29-31, 2014 in Chicago, ... be to connect with global leaders in clinical chemistry, ... other areas of breaking science in laboratory medicine. , ...
(Date:7/23/2014)... MA (PRWEB) July 23, 2014 ... of innovative and comprehensive consultancy and pharma training ... Excellence and Safety (ACRES) , a non-profit integrating ... to build and maintain a global system for ... alliance collaboration to improve the expertise of industry ...
(Date:7/22/2014)... July 22, 2014 The Board of Directors of ... has declared a quarterly dividend of 54.5 cents per common ... on September 9, 2014. The indicated annual dividend rate is ... BD is a leading medical technology company that partners with ... pressing and evolving health needs. Our innovative solutions are focused ...
Breaking Biology Technology:Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3
... This release is available in French . Physicists ... energy involved in adding electrons to semi-conductor nanocrystals, also known ... and other areas of science. Dr. Peter Grtter, McGill,s Associate ... that his research team has developed a cantilever force sensor ...
... EDMONTON , May 11 ... company focused on developing medical device,products for use ... it has,received regulatory concurrence from the United States ... product, Occlusin(R) 500 Artificial,Embolization Device (OCL 500) in ...
... ORLANDO, Fla. , May 11 GeneLink, Inc. (OTC Bulletin ... quarter ended March 31, 2010 . , , ... , , , ... Quarterly operating loss reduced by 14% over Q4 2009 Comparable quarter gross profit improvement ...
Cached Biology Technology:Quantum move toward next generation computing 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 3GeneLink Reports First Quarter Gains 2
(Date:7/22/2014)... National Institute of Standards and Technology (NIST), working ... improved technique for analyzing biological cells and tissues ... NIST technique is an advanced form of the ... delivers signals that are 10,000 times stronger than ... stronger than obtained from comparable "coherent Raman" instruments, ...
(Date:7/22/2014)... Rochelle, NY -- Stem cells offer much promise for ... approaches stem cell survival is poor, limiting their effectiveness. ... the survival and optimize their therapeutic function after transplantation, ... Open Access , a peer-reviewed journal from Mary Ann ... the BioResearch Open Access website . ...
(Date:7/22/2014)... July 22, 2014 BGI Tech Solutions Co., ... world,s largest genomics organization, announced today the global ... service based on Complete Genomics, industry-leading platform. This ... SNP validation, and is available at reduced prices ... highly regarded in the industry for providing proprietary ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2
... developing bipolar disorder depends in part on the combined, small ... brain, none of which is powerful enough to cause the ... the enzyme produced by one of these genes could lead ... was conducted by scientists at the National Institutes of Health's ...
... their effects on fat development, researchers have discovered that ... mice without some of the side effects attributed to ... harmine, was first isolated more than 150 years ago ... around the world, the team reports in the May ...
... it express who we are, but is it really possible to ... to that question seems to be related to fashion and glamour, ... Mexico and the Buck Institute in the USA, were able to ... In biology, the capacity to establish the function of a molecule, ...
Cached Biology News:Genetic roots of bipolar disorder revealed by first genome-wide study of illness 2Genetic roots of bipolar disorder revealed by first genome-wide study of illness 3Fat screen delivers plant-derived chemical with antidiabetic effects 2
Tissue culture grade....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... ideal for both radioactive and nonradioactive labeling ... Provides five pre-mixed nucleotide solutions for flexibility ... 8 cpm/g control DNA using [-32P]-dCTP ... performance of the system Labels 1 ...
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: